ClearPoint Neuro (CLPT) Set to Release Quarterly Earnings on Wednesday

Key Points

• ClearPoint Neuro is expected to report Q3 2026 results after market close on October 28. Analysts forecast a loss of $0.27 per share and revenue of $12.30 million.
• The company missed estimates in its previous quarter, reporting a $0.38-per-share loss and $10.88 million in revenue versus expectations of a $0.29 loss and $12.73 million in revenue.
• Analyst sentiment is mixed, with an average rating of “Hold” and a consensus price target of $25.67, while the stock recently traded at $9.45—well below its 52-week high of $27.27.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect ClearPoint Neuro to announce earnings of ($0.27) per share and revenue of $12.30 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.09). The business had revenue of $10.88 million during the quarter, compared to analyst estimates of $12.73 million. ClearPoint Neuro had a negative net margin of 81.76% and a negative return on equity of 188.09%. During the same quarter in the prior year, the company posted ($0.21) earnings per share. On average, analysts expect ClearPoint Neuro to post ($1.22) EPS for the current fiscal year and ($1.16) EPS for the next fiscal year.

ClearPoint Neuro Trading Up 3.1%

Shares of ClearPoint Neuro stock opened at $9.45 on Wednesday. The firm has a market capitalization of $288.23 million, a price-to-earnings ratio of -8.01 and a beta of 1.29. ClearPoint Neuro has a fifty-two week low of $8.27 and a fifty-two week high of $27.27. The company has a debt-to-equity ratio of 4.66, a quick ratio of 3.89 and a current ratio of 4.74. The stock has a 50 day moving average of $13.37 and a 200 day moving average of $13.51.

Analyst Ratings Changes

Several brokerages have recently commented on CLPT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ClearPoint Neuro in a research note on Thursday, October 15th. Wall Street Zen downgraded ClearPoint Neuro from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Stifel Nicolaus set a $22.00 price objective on ClearPoint Neuro in a research report on Tuesday, August 4th. Finally, Lake Street Capital set a $25.00 price objective on shares of ClearPoint Neuro in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $25.67.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes image-guided systems for minimally invasive neurosurgical procedures. Its platform is designed to help physicians plan, navigate and monitor procedures within the brain, using magnetic resonance imaging (MRI) to support accurate placement of instruments and therapeutic agents.

The company's product portfolio includes the ClearPoint Neuro navigation system and related disposable components, including cranial access and guidance products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.